Recent changes

Jump to: navigation, search

Track the most recent changes to the wiki on this page.

Recent changes options
Legend:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes
Show last 50 | 100 | 250 | 500 changes in last 1 | 3 | 7 | 14 | 30 days
Hide registered users | Hide anonymous users | Hide my edits | Show bots | Hide minor edits
Show new changes starting from 17:34, 16 October 2019
   

15 October 2019

     21:06  Editorial Board‎ (diff | hist) . . (+1,402)‎ . . Warner-admin (talk | contribs)
 m   21:02  User:Donnarivera‎ (diff | hist) . . (+66)‎ . . Warner-admin (talk | contribs)
 m   20:57  Response to treatment‎‎ (2 changes | history) . . (+22)‎ . . [Jwarner‎ (2×)]
 m    20:57 (cur | prev) . . (-1)‎ . . Jwarner (talk | contribs)
 m    20:56 (cur | prev) . . (+23)‎ . . Jwarner (talk | contribs)
 m   20:31  Acute myeloid leukemia‎ (diff | hist) . . (+627)‎ . . Jwarner (talk | contribs) (→‎Prognosis in cytogenetically normal AML)
     15:28  (User creation log)‎ . . [Bishalgyawali‎; Ashish.massey‎]
      15:28 . . User account Ashish.massey (talk | contribs) was created ‎
      07:58 . . User account Bishalgyawali (talk | contribs) was created ‎
 m   13:48  Breast cancer, ER/PR-positive‎‎ (2 changes | history) . . (+36)‎ . . [Jwarner‎ (2×)]
 m    13:48 (cur | prev) . . (+18)‎ . . Jwarner (talk | contribs) (→‎Letrozole monotherapy {{#subobject:230132|Regimen=1}})
 m    13:36 (cur | prev) . . (+18)‎ . . Jwarner (talk | contribs) (→‎Variant #3, 40 mg/day {{#subobject:de3aaf|Variant=1}})
N    08:05  User:Bishalgyawali‎ (diff | hist) . . (+1,202)‎ . . PeterYang (talk | contribs) (Created page with "thumb|Bishal Gyawali, MD, PhD Bishal Gyawali, MD, PhD is currently an assistant professor in the Department of Public Health Sciences, scientist in...")
     08:05 (Upload log) . . PeterYang (talk | contribs) uploaded File:Bishalgyawali.jpg ‎(Bishal Gyawali, MD, PhD headshot photo.)

14 October 2019

 m   11:42  Category:T-cell acute lymphoblastic leukemia regimens‎ (diff | hist) . . (+38)‎ . . Jwarner (talk | contribs)
 m   11:41  Category:Adult T-cell leukemia/lymphoma regimens‎ (diff | hist) . . (+7)‎ . . Jwarner (talk | contribs)
N    11:41  Category:T-cell leukemia regimens‎ (diff | hist) . . (+30)‎ . . Jwarner (talk | contribs) (Created page with "Category:Leukemia regimens")
N    11:40  Category:T-cell prolymphocytic leukemia regimens‎ (diff | hist) . . (+37)‎ . . Jwarner (talk | contribs) (Created page with "Category:T-cell leukemia regimens")
N    11:40  T-cell prolymphocytic leukemia‎ (diff | hist) . . (+1,500)‎ . . Jwarner (talk | contribs) (Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor''' |- |s...")
     11:37  Main Page‎ (diff | hist) . . (+218)‎ . . Warner-admin (talk | contribs)
     05:46 (User creation log) . . User account Mwpharmd33 (talk | contribs) was created ‎

13 October 2019

 m   20:59  Breast cancer‎‎ (3 changes | history) . . (+1,978)‎ . . [Jwarner‎ (3×)]
 m    20:59 (cur | prev) . . (-560)‎ . . Jwarner (talk | contribs) (→‎Adjuvant chemotherapy)
 m    20:22 (cur | prev) . . (+2,270)‎ . . Jwarner (talk | contribs) (→‎FEC {{#subobject:ed96e7|Regimen=1}})
 m    10:13 (cur | prev) . . (+268)‎ . . Jwarner (talk | contribs) (→‎Neoadjuvant chemotherapy)
 m   20:26  Response to treatment‎‎ (5 changes | history) . . (+1,115)‎ . . [Jwarner‎ (5×)]
 m    20:26 (cur | prev) . . (+440)‎ . . Jwarner (talk | contribs) (→‎Invasive disease free survival (IDFS))
 m    20:18 (cur | prev) . . (+51)‎ . . Jwarner (talk | contribs) (→‎Relapse-free interval (RFI))
 m    20:01 (cur | prev) . . (+36)‎ . . Jwarner (talk | contribs) (→‎Primary refractory disease)
 m    18:16 (cur | prev) . . (+454)‎ . . Jwarner (talk | contribs)
 m    18:10 (cur | prev) . . (+134)‎ . . Jwarner (talk | contribs) (→‎Recurrence- or Relapse-free survival (RFS))
     18:15  (Upload log)‎ . . [Jwarner‎ (2×)]
      18:15 . . Jwarner (talk | contribs) uploaded a new version of File:Bishal gyawali.jpg ‎
      18:13 . . Jwarner (talk | contribs) uploaded File:Bishal gyawali.jpg ‎
 m   09:26  Acute myeloid leukemia‎ (diff | hist) . . (+131)‎ . . Jwarner (talk | contribs) (→‎First-line induction therapy, older or "unfit" patients)

12 October 2019

 m   22:36  Non-small cell lung cancer‎ (diff | hist) . . (+2,305)‎ . . Jwarner (talk | contribs) (→‎Advanced or metastatic disease, first-line)
 m   16:52  Multiple myeloma, relapsed/refractory‎‎ (2 changes | history) . . (-504)‎ . . [Jwarner‎ (2×)]
 m    16:52 (cur | prev) . . (+204)‎ . . Jwarner (talk | contribs) (→‎Maintenance after second-line therapy)
 m    16:51 (cur | prev) . . (-708)‎ . . Jwarner (talk | contribs) (→‎Relapsed or refractory, randomized data)
 m   16:35  Multiple myeloma, consolidation and maintenance‎ (diff | hist) . . (+166)‎ . . Jwarner (talk | contribs)
 m   16:34  Response to treatment‎ (diff | hist) . . (+57)‎ . . Jwarner (talk | contribs) (→‎Progression-free survival rate at 18 months (PFS18))

11 October 2019

 m   23:30  Non-small cell lung cancer‎ (diff | hist) . . (+13,373)‎ . . Jwarner (talk | contribs) (→‎Advanced or metastatic disease, subsequent lines of therapy)
 m   23:22  Response to treatment‎‎ (3 changes | history) . . (+57)‎ . . [Jwarner‎ (3×)]
 m    23:22 (cur | prev) . . (-43)‎ . . Jwarner (talk | contribs) (→‎Overall survival rate at 1 year (OS1))
 m    23:21 (cur | prev) . . (+43)‎ . . Jwarner (talk | contribs) (→‎Progression-free survival rate at 6 months (PFS6))
 m    20:47 (cur | prev) . . (+57)‎ . . Jwarner (talk | contribs) (→‎Progression-free survival rate at 6 months (PFS6))
 m   21:59  Vosaroxin (SNS 595)‎ (diff | hist) . . (+691)‎ . . Jwarner (talk | contribs) (→‎Acute myeloid leukemia)
N    21:40  Value frameworks‎ (diff | hist) . . (+3,106)‎ . . Jwarner (talk | contribs) (Created page with " =Introduction= Several leading hematology/oncology societies and organizations have put forth value frameworks. Conceptually, these are approaches which are intended to combi...")
 m   21:36  Levels of Evidence‎ (diff | hist) . . (-2,924)‎ . . Warner-admin (talk | contribs)
 m   20:49  Multiple myeloma, induction‎ (diff | hist) . . (+674)‎ . . Jwarner (talk | contribs)
 m   16:00  Complex multipart regimens‎ (diff | hist) . . (+37)‎ . . Jwarner (talk | contribs) (→‎Comparative efficacy)
 m   15:52  Hodgkin lymphoma‎ (diff | hist) . . (+535)‎ . . Jwarner (talk | contribs) (→‎Pembrolizumab monotherapy {{#subobject:85b287|Regimen=1}})
 m   09:54  Breast cancer, ER/PR-positive‎ (diff | hist) . . (+252)‎ . . Jwarner (talk | contribs) (→‎Metastatic disease, subsequent lines of endocrine therapy)

10 October 2019

 m   22:54  Breast cancer, ER/PR-positive‎ (diff | hist) . . (+653)‎ . . Jwarner (talk | contribs) (→‎Metastatic disease, first-line endocrine therapy)
 m   21:35  Acute myeloid leukemia‎ (diff | hist) . . (+613)‎ . . Jwarner (talk | contribs) (→‎References)

9 October 2019

 m   20:27  Response to treatment‎ (diff | hist) . . (+192)‎ . . Jwarner (talk | contribs) (→‎General response rates)
Retrieved from "https://hemonc.org/wiki/Special:RecentChanges"